Replimune Group Inc. (REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, has a regulatory catalyst to watch next month.
The company's lead investigational product, RP1 (vusolimogene odeparepvec), is an oncolytic therapy derived from a genetically engineered strain of the herpes simplex virus. RP1, in combination with Bristol Myers Squibb's checkpoint inhibitor Opdivo, is under investigation for advanced melanoma, with the FDA decision due on April 10, 2026.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com